Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 670-673

  Sipahi, Oguz Resat ^a   Turhan, Tuncer ^a   Pullukcu, Husnu ^a   Calik, Sebnem ^a   Tasbakan, Meltem ^a   Sipahi, Hilal ^a   Arda, Bilgin ^a   Yamazhan, Tansu ^a   Ulusoy, Sercan ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Central nervous system infections; Listeriosis; Quinolones; Rabbits

Indexed keywords

AMPICILLIN; GENTAMICIN; MOXIFLOXACIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CEREBROSPINAL FLUID CULTURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; INCUBATION TIME; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; NONHUMAN; RABBIT;

AMPICILLIN; ANIMALS; AZA COMPOUNDS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENTAMICINS; HUMANS; MALE; MENINGITIS, LISTERIA; QUINOLINES; RABBITS;

EID: 40049097389     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn001     Document Type: Article

References (13)

1. Hof H, Nichterlein T, Kretschmar M. Management of listeriosis. Clin Microbiol Rev 1997; 10: 345-57.
2. Levidiotou S, Charalabopoulos K, Vrioni G et al. Fatal meningitis due to Listeria monocytogenes in elderly patients with underlying malignancy. Int J Clin Pract 2004; 58: 292-6.
3. Scheld WM, Fletcher DD, Fink FN et al. Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes. J Infect Dis 1979; 140: 287-94.
4. Carryn S, Van Bambeke F, Mingeot-Leclercq MP et al. Activity of β-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J Antimicrob Chemother 2003; 51 1051-2.
5. Rolston KV, Frisbee-Hume S, LeBlanc B et al. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis 2003; 47: 441-9.
6. Rodriguez-Cerrato V, McCoig CC, Saavedra J et al. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob Agents Chemother 2003; 47: 211-5.
7. Rodriguez-Cerrato V, McCoig CC, Michelow IC et al. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother 2001; 45: 3092-7.
8. Seral C, Barcia-Macay M, Mingeot-Leclercq MP et al. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against, extracellular, and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 2005; 55: 511-7.
9. Hof H. An update on the medical management of listeriosis. Expert Opin Pharmacother 2004; 5: 1727-35.
10. Nichterlein T, Bornitz F, Kretschmar M et al. Successful treatment of murine listeriosis and salmonellosis with levofloxacin. J Chemotherapy 1998; 10: 313-9.
11. Nichterlein T, Bornitz F, Kretschmar M et al. The activity of moxifloxacin, a new 8-methoxyquinolone, against strains of salmonellae and Listeria monocytogenes in vitro, in mouse infections and in infected tissue cells. In: Adam D, Finch R, eds. Moxifloxacin in Practice (Vol. 2). Oxford, UK: Maxim Medical, 1999; 71-82.
12. Schmidt H, Dalhoff A, Stuertz K et al. Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother 1998; 42: 1397-407.
13. Viale P, Furlanut M, Cristini F et al. Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis. Diagn Microbiol Infect Dis 2007; 58: 137-9.